ANXA3 and hepatocellular carcinoma: Tong et al.33 have shown in sorafenib non-responsive HCC in vivo models that co-administration of regorafenib and an anti-ANXA-3 monoclonal antibody can enhance apoptotic induction because of the abolishment of autophagy.